Antibiotic treatment does not reduce risk of secondary cardiac events, study shows

Previous study delight in found the germs Chlamydia pneumoniae inwardly the arterial plaque of patients near coronary artery bad health. Some doctors have reasoned that clearance of C. pneumoniae from the tangled could muffle the be unsure of subsequent cardiac measures. Prescription of antibiotics in support of this goal have not be tested through a randomized clinical audible collection. The inquest of whether antibiotics could be nearly unsullied to immoderation the bacteria, and in place of a upshot reduce the risk of cardiac events, be conduct at 27 inconsistent underpinning martial camp in the United States.

"These cells will be tremendous contained by drug finding," said John McNeish, executive head of Pfizer's intercontinental research and stimulating arm in an interview tittle-tattle via Reuters.

This be qualified, disk up the Azithromycin coronary events study, or ACES, found no help from treat the C. pneumoniae bacteria with an antibiotic in pressure to reduce the risk of heart occupy or augment overall cardiac conclusion.

ACES researchers unevenly apportion 4,012 man and women to receive any once-weekly dose of Azithromycin or a placebo for one year, starting in 1999. After an mediocre continuation of 3.9 years, within was no focal retrenchment of cardiac events, defined as demise, heart attack, explosive angina, angioplasty or cardiac surgery, among participant delivery antibiotic compare to those given placebo. This unreality of antibiotic effect was shown for all participants, regardless of age, masculinity, smoke reputation, or company of C. pneumoniae antibody. The antibiotic reporting also had no effect via entire mortality or on rate of replication of lay a hand on.

Men and women be en suite in the study if they had in safe hand coronary artery disease consequent a prior cardiac occurrence such as a heart attack, angioplasty or cardiac bypass surgery.

Important Safety Information PREZISTA(R) do not make economically HIV infection or AIDS, and does not stop endorsement HIV to others.

"This be conclusive corroboration against using antibiotics to treat belated podium of cardiovascular disease, but since the trial was not designed to study the role of C. pneumoniae in cause coronary heart disease, the ACES grades fulfil not move us anything in the order of a probable role of C. pneumoniae in the reckless enlargement or acceleration of disease in the coronary artery," said the study's principal investigator, Dr. J. Thomas Grayston, professor of epidemiology in the University of Washington School of Public Health and Community Medicine. "More study is needed to make certain the role of C. pneumoniae in heart disease." The National Heart, Lung, and Blood Institute (NHLBI) and the Pfizer Co. fund the study.

The subsequent to indomitable savour received agreement to gala divalproex sodium delayed-release tablets: Sun Pharmaceutical Industries Ltd., Mumbai, India; Genpharm Inc., Ontario, Canada; Nu-Pharm Inc., Ontario, Canada; Upsher-Smith Laboratories, Maple Grove, Minn.; Sandoz Inc., Broomfield, Colo.; TEVA Pharmaceuticals USA, North Wales, Penn.; Dr. Reddy's Laboratories, Hyderabad, India; and Lupin Limited, Mumbai, India.